Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fosaprepitant versus aprepitant for prevention of highly emetogenic chemotherapy-induced nausea and vomiting
CTR20160836Phase 3Completed
- Sponsor
- Jiangsu Aosaikang Pharmaceutical Co., Ltd.
- Start
- Jan 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of fosaprepitant in chemotherapy-induced nausea and vomiting (CINV), sponsored by Jiangsu Aosaikang Pharmaceutical Co., Ltd.. Started Jan 2017; status: completed.
02
Drugs
fosaprepitant
03
Conditions
chemotherapy-induced nausea and vomiting (CINV)
Beyond the preview
Go deeper on CTR20160836.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20160836.